DDX5 Inhibits Hyaline Cartilage Fibrosis and Degradation in Osteoarthritis via Alternative Splicing and G-Quadruplex Unwinding

The Novel Mechanism of DDX5 in Inhibiting Hyaline Cartilage Fibrosis and Degradation in Osteoarthritis Background Osteoarthritis (OA) is a chronic degenerative disease characterized mainly by the degradation, degeneration, and osteophyte formation of joint cartilage. Hyaline cartilage fibrosis is often considered the end-stage lesion of OA, leading...

Efficacy-Effectiveness Analysis on Survival in a Population-Based Real-World Study of BRAF-Mutated Metastatic Colorectal Cancer Patients Treated with Encorafenib-Cetuximab

Efficacy-Effectiveness Analysis of Encorafenib-Cetuximab Treatment in Patients with Oncogene-Mutated Metastatic Colorectal Cancer: A Cohort Study Research Background With the advancement of personalized medicine, targeted therapy has become an important means to treat various cancers. In metastatic colorectal cancer (mCRC), the combination of encor...

Empowering Glioma Prognosis with Transparent Machine Learning and Interpretative Insights Using Explainable AI

Enabling Explainable Artificial Intelligence for Glioma Prognosis: Translational Insights from Transparent Machine Learning Academic Background This study is dedicated to developing a reliable technique to detect whether patients have a specific type of brain tumor—glioma—using various machine learning methods and deep learning methods, combined wi...

CHD2 Regulates Neuron-Glioma Interactions in Pediatric Glioma

Research Report on the Regulation of Neuron-Glioma Interactions by CHD2 in Pediatric Gliomas Background High-grade gliomas (HGG) are fatal diseases in both adult and pediatric patients. Recent studies have shown that neuronal activity can promote the progression of various high-grade glioma subgroups. However, the epigenetic mechanisms regulating t...

D3S-001: A KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Inhibits Nucleotide Cycling and Demonstrates Robust Preclinical and Clinical Activity Background Introduction The KRAS (Kirsten rat sarcoma viral oncogene homolog) gene mutation is one of the oncogenic drivers in various solid tumors (such as non-small cell lung cancer (NSCLC) an...